Elutia Inc. (ELUT)

NCM – Real Time Price. Currency in USD

1.05

-0.01 (-0.94%)

Market open: May 12, 2026, 4:00 PM EDT

1.05

0.00 (0.00%)

Previous after-hours: May 12, 2026, 4:10 PM EDT

17.03.2026

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, PhD, Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small-Cap Virtual Investor Conference, taking place March 18–19, 2026.

13.03.2026

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).

12.03.2026

Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript

11.03.2026

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m.

04.03.2026

Elutia Regains Compliance with Nasdaq Listing Requirements

GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2).

02.03.2026

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer.

25.02.2026

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026.

Videos

No Data

There is no data to display

Press releases

13.03.2026

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

11.03.2026

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

04.03.2026

Elutia Regains Compliance with Nasdaq Listing Requirements

02.03.2026

Elutia Inc. (ELUT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Elutia Inc. (ELUT)

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Videos

No Data

Press releases

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Videos

No Data

Press releases

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Search stocks

Elutia Inc. (ELUT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Elutia Inc. (ELUT)

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Videos

No Data

Press releases

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Videos

No Data

Press releases

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market